NCT05498207 Identification of Biomarkers for Stress Vulnerability and Resilience
| NCT ID | NCT05498207 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-08-23 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2022-08-23 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to understand the biological mechanisms of stress vulnerability (being susceptible to stress) and stress resilience (being able to recover readily from stress), obtain biomarkers (a biological indicator) for stress resilience and to devise strategies for prevention and treatment of stress-related disorders.
Eligibility Criteria
Inclusion Criteria: * Incoming Freshmen Students at the University of Michigan Exclusion Criteria: * Suicidal Ideation
Contact & Investigator
Huda Akil, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT05498207 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 22 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05498207 currently recruiting?
Yes, NCT05498207 is actively recruiting participants. Contact the research team at gweinber@umich.edu for enrollment information.
Where is the NCT05498207 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT05498207 clinical trial?
NCT05498207 is sponsored by University of Michigan. The principal investigator is Huda Akil, PhD at University of Michigan. The trial plans to enroll 500 participants.